Cargando…

Syringin exerts anti-breast cancer effects through PI3K-AKT and EGFR-RAS-RAF pathways

BACKGROUND: Breast cancer (BC) is one of the most common malignant tumors with the highest mortality in the world. Modern pharmacological studies have shown that Syringin has an inhibitory effect on many tumors, but its anti-BC efficacy and mechanism are still unclear. METHODS: First, Syringin was i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Fei, Yuan, Chong, Liu, Bo, Yang, Yan-Fang, Wu, He-Zhen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258109/ https://www.ncbi.nlm.nih.gov/pubmed/35794555 http://dx.doi.org/10.1186/s12967-022-03504-6

Ejemplares similares

Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis
por: Fritsche-Guenther, Raphaela, et al.
Publicado: (2016)

CB-RAF600E-1 exerts efficacy in vemurafenib-resistant and non-resistant-melanoma cells via dual inhibition of RAS/RAF/MEK/ERK and PI3K/Akt signaling pathways
por: Al Shahrani, Mesfer, et al.
Publicado: (2022)

Does Ras Activate Raf and PI3K Allosterically?
por: Nussinov, Ruth, et al.
Publicado: (2019)

RAS/RAF/MEK/ERK and PI3K/PTEN/AKT Signaling in Malignant Melanoma Progression and Therapy
por: Yajima, Ichiro, et al.
Publicado: (2012)

GE11 peptide conjugated selenium nanoparticles for EGFR targeted oridonin delivery to achieve enhanced anticancer efficacy by inhibiting EGFR-mediated PI3K/AKT and Ras/Raf/MEK/ERK pathways
por: Pi, Jiang, et al.
Publicado: (2017)

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
por: Chappell, William H., et al.
Publicado: (2011)

Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer
por: Butler, Dominika E., et al.
Publicado: (2017)

In Ovo and In Silico Evaluation of the Anti-Angiogenic Potential of Syringin
por: Aventurado, Charlaine A, et al.
Publicado: (2020)

Fangchinoline exerts antitumour activity by suppressing the EGFR-PI3K/AKT signalling pathway in colon adenocarcinoma
por: Jiang, Fengqi, et al.
Publicado: (2021)

IGF-1R down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the PI3K / akt and RAS / raf / ERK signaling pathways
por: Cai, Wenpeng, et al.
Publicado: (2023)

Dihydroartemisinin inhibits the Raf/ERK/MEK and PI3K/AKT pathways in glioma cells
por: Du, Wei, et al.
Publicado: (2021)

Correlation of LAGE3 with unfavorable prognosis and promoting tumor development in HCC via PI3K/AKT/mTOR and Ras/RAF/MAPK pathways
por: Li, Yun, et al.
Publicado: (2022)

Modulation of the Akt/Ras/Raf/MEK/ERK pathway by A(3) adenosine receptor
por: Merighi, Stefania, et al.
Publicado: (2006)

Protein and lipid kinase inhibitors as targeted anticancer agents of the Ras/Raf/MEK and PI3K/PKB pathways
por: García-Echeverría, Carlos
Publicado: (2008)

Mutation analysis of key genes in RAS/RAF and PI3K/PTEN pathways in Chinese patients with hepatocellular carcinoma
por: HOU, WENMIN, et al.
Publicado: (2014)

Syringin exerts anti‐inflammatory and antioxidant effects by regulating SIRT1 signaling in rat and cell models of acute myocardial infarction
por: Zhao, Di, et al.
Publicado: (2023)

A New EGFR Inhibitor from Ficus benghalensis Exerted Potential Anti-Inflammatory Activity via Akt/PI3K Pathway Inhibition
por: Alaaeldin, Rania, et al.
Publicado: (2022)

Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response
por: McCubrey, James A., et al.
Publicado: (2012)

Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
por: Li, Qingfang, et al.
Publicado: (2022)

Ras and Raf pathways in epidermis development and carcinogenesis
por: Kern, F, et al.
Publicado: (2011)

Ras and Raf pathways in epidermis development and carcinogenesis
por: Kern, F, et al.
Publicado: (2011)

Intra-Cellular Calcium Signaling Pathways (PKC, RAS/RAF/MAPK, PI3K) in Lamina Cribrosa Cells in Glaucoma
por: Irnaten, Mustapha, et al.
Publicado: (2020)

TPX2 silencing exerts anti-tumor effects on hepatocellular carcinoma by regulating the PI3K/AKT signaling pathway
por: Huang, Dan-Hong, et al.
Publicado: (2019)

An engineered protein antagonist of K-Ras/B-Raf interaction
por: Kauke, Monique J., et al.
Publicado: (2017)

RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition
por: Jin, Ting, et al.
Publicado: (2017)

Bicyclol induces cell cycle arrest and autophagy in HepG2 human hepatocellular carcinoma cells through the PI3K/AKT and Ras/Raf/MEK/ERK pathways
por: Wang, Yu, et al.
Publicado: (2016)

Terpenoid natural products exert neuroprotection via the PI3K/Akt pathway
por: Xu, Bingyao, et al.
Publicado: (2022)

Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras
por: Akutagawa, Jon, et al.
Publicado: (2016)

Clonorchis sinensis Granulin Promotes Malignant Transformation of Hepatocyte Through EGFR-Mediated RAS/MAPK/ERK and PI3K/Akt Signaling Pathways
por: Wang, Caiqin, et al.
Publicado: (2021)

TSPAN7 Exerts Anti-Tumor Effects in Bladder Cancer Through the PTEN/PI3K/AKT Pathway
por: Yu, Xi, et al.
Publicado: (2021)

Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade
por: Yan, Chi, et al.
Publicado: (2021)

Role of autophagy in K-RAS- and B-RAF-driven lung cancers
por: White, Eileen
Publicado: (2014)

Capsaicin and sorafenib combination treatment exerts synergistic anti-hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling
por: Dai, Ninggao, et al.
Publicado: (2018)

Repression of CD24 surface protein expression by oncogenic Ras is relieved by inhibition of Raf but not MEK or PI3K
por: Pallegar, Nikitha K., et al.
Publicado: (2015)

FOXD3 is a tumor suppressor of colon cancer by inhibiting EGFR-Ras-Raf-MEK-ERK signal pathway
por: Li, Kun, et al.
Publicado: (2016)

The Hippo Tumor Suppressor Pathway (YAP/TAZ/TEAD/MST/LATS) and EGFR-RAS-RAF-MEK in cancer metastasis
por: Zinatizadeh, Mohammad Reza, et al.
Publicado: (2019)

K-ras/PI3K-Akt Signaling Is Essential for Zebrafish Hematopoiesis and Angiogenesis
por: Liu, Lihui, et al.
Publicado: (2008)

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance
por: McCubrey, James A., et al.
Publicado: (2012)

Allosteric modulation of Ras and the PI3K/AKT/mTOR pathway: emerging therapeutic opportunities
por: Hubbard, Paul A., et al.
Publicado: (2014)

Alterations in the RTK/Ras/PI3K/AKT pathway serve as potential biomarkers for immunotherapy outcome of diffuse gliomas
por: Han, Song, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l0d572mr7e89bpfe8augemtgdb